Healthcare / BiotechnologyNasdaqCM
$3.08
-0.18 (-5.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-2.6M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$154M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-196.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-9.0M · FCF $-3.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Net Income | $-9.0M | $-9.0M | $-30.4M | $-3.8M |
| EBITDA | $-7.8M | $-7.8M | $-4.4M | $-3.8M |
| EPS | — | — | -0.64 | -0.08 |
| Balance Sheet | ||||
| Debt/Equity | — | — | — | 0.10 |
| Current Ratio | 3.45 | 3.45 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-3.9M | $-3.9M | $-2.6M | $-173000.00 |
| Returns | ||||
| ROE | -196.8% | -196.8% | -644.2% | -295.9% |
| Valuation | ||||
| P/B | 31.99 | 31.99 | — | — |
| Growth & Yield | ||||
| EPS Growth | — | — | -703.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-91.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.64 → n/d
Residual
-91.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.